Current concepts in multiple sclerosis: Autoimmunity versus oligodendrogliopathy

Clinical Reviews in Allergy and Immunology

Volumn 42, Issue 1, 2012, Pages 26-34

  Nakahara, Jin ^a   Maeda, Michiko ^a   Aiso, Sadakazu ^a   Suzuki, Norihiro ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Autoimmune; Multiple sclerosis; Oligodendrogliopathy; Pathogenesis

Indexed keywords

ALEMTUZUMAB; CLADRIBINE; FINGOLIMOD; RITUXIMAB; TERIFLUNOMIDE;

ARTICLE; AUTOIMMUNITY; CLINICAL FEATURE; DEMYELINATION; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; INFLAMMATION; LONG TERM CARE; MORBIDITY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; MULTIPLE SCLEROSIS; OLIGODENDROGLIA;

EID: 84857052288     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-011-8287-6     Document Type: Article

References (68)

1. The IFNβ Multiple Sclerosis Study Group 1993 Interferon β-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial Neurology 43 655 661
2. The Multiple Sclerosis Collaborative Research Group 1996 Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis Ann Neurol 39 285 294 10.1002/ana.410390304 (Pubitemid 26100751)
3. The Copolymer 1 Multiple Sclerosis Study Group 1995 Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial Neurology 45 1268 1276
4. C Confavreux S Vukusic 2006 Natural history of multiple sclerosis: a unifying concept Brain 129 606 616 16415308 10.1093/brain/awl007 (Pubitemid 43278223)
5. MH Barnett JW Prineas 2004 Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion Ann Neurol 55 458 468 15048884 10.1002/ana.20016 (Pubitemid 38391962)
6. APD Henderson MH Barnett JDE Parratt, et al. 2009 Multiple sclerosis: distribution of inflammatory cells in newly forming lesions Ann Neurol 66 739 753 20035511 10.1002/ana.21800
7. GC Furtado MC Marcondes JA Latkowski, et al. 2008 Swift entry of myelin-specific T lymphocytes into the central nervous system in spontaneous autoimmune encephalomyelitis J Immunol 181 4648 4655 18802067 1:CAS:528:DC%2BD1cXhtFarurzP
8. DJ Cua J Sherlock Y Chen, et al. 2003 Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain Nature 421 744 748 12610626 10.1038/nature01355 1:CAS:528:DC%2BD3sXhsV2rsbs%3D (Pubitemid 36227625)
9. JS Tzartos MA Friese MJ Craner, et al. 2008 Interleukin-17 production in central nervous system-infiltrating T cells and glial cells associated with active disease in multiple sclerosis Am J Pathol 172 146 155 18156204 10.2353/ajpath.2008.070690 1:CAS:528:DC%2BD1cXhslOmur0%3D (Pubitemid 351186376)
10. A Reboldi C Coisne D Baumjohann, et al. 2009 C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE Nat Immunol 10 514 523 19305396 10.1038/ni.1716 1:CAS:528:DC%2BD1MXjsVGjs7Y%3D
11. E Esplugues S Huber N Gagliani, et al. 2011 Controls of Th17 cells occurs in the small intestine Nature 475 514 518 21765430 10.1038/nature10228 1:CAS:528:DC%2BC3MXovFygsrc%3D
12. DA Brown PE Sawchenko 2007 Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis J Comp Neurol 502 236 260 17348011 10.1002/cne.21307 (Pubitemid 46595397)
13. I Bartholomäus N Kawakami F Odoardi, et al. 2009 Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions Nature 462 94 98 19829296 10.1038/nature08478
14. Y Pang L Campbell B Zheng, et al. 2010 Lipopolysaccharide-activated microglia induce death of oligodendrocyte progenitor cells and impede their development Neuroscience 166 464 475 20035837 10.1016/j.neuroscience.2009.12.040 1:CAS:528:DC%2BC3cXitVejs7g%3D
15. AP Lieberman PM Pitha HS Shin, et al. 1989 Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus Proc Natl Acad Sci USA 86 6348 6352 2474832 10.1073/pnas.86.16.6348 1:CAS:528:DyaL1MXlslaitr0%3D (Pubitemid 19210649)
16. HP Eugster K Frei R Bachmann, et al. 1999 Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1 Eur J Immunol 29 626 632 10064079 10.1002/(SICI)1521-4141(199902)29:02<626::AID-IMMU626>3.0.CO;2-A 1:CAS:528:DyaK1MXhsVams70%3D (Pubitemid 29078524)
17. HA Arnett J Mason M Marino K Suzuki GK Matsushima JPY Ting 2001 TNFα promotes proliferation of oligodendrocyte progenitors and remyelination Nat Neurosci 4 1116 1122 11600888 10.1038/nn738 1:CAS:528:DC%2BD3MXot1ajsrc%3D (Pubitemid 34116557)
18. S Sriram I Steiner 2005 Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis Ann Neurol 58 939 945 16315280 10.1002/ana.20743 1:CAS:528:DC%2BD2MXhtlaks7jP (Pubitemid 41746884)
19. TM Rivers DH Sprunt GP Berry 1933 Observations on attempts to produce acute disseminated encephalomyelitis in monkeys J Exp Med 58 39 53 19870180 10.1084/jem.58.1.39 1:STN:280:DC%2BC3crhvFylsw%3D%3D
20. L Steinman SS Zamvil 2006 How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis Ann Neurol 60 12 21 16802293 10.1002/ana.20913 1:CAS:528:DC%2BD28XnsFSrsL0%3D
21. MK Waldor S Sriram R Hardy, et al. 1985 Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker Science 227 415 417 3155574 10.1126/science.3155574 1:STN:280:DyaL2M%2FptVCnsQ%3D%3D (Pubitemid 15153498)
22. BW van Oosten M Lai S Hodgkinson, et al. 1997 Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial Neurology 49 351 357 9270561
23. NH Ruddle CM Bergman KM McGrath, et al. 1990 An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis J Exp Med 172 1193 1200 2212948 10.1084/jem.172.4.1193 1:CAS:528:DyaK3cXlslSitb8%3D (Pubitemid 20343220)
24. K Selmaj CS Raine AH Cross 1991 Anti-tumor necrosis factor therapy abrogates autoimmune demyelination Ann Neurol 30 694 700 1722388 10.1002/ana.410300510 1:STN:280:DyaK387gvFCguw%3D%3D
25. The Lenercept Multiple Sclerosis Study Group The University of British Columbia MS/MRI Analysis Group 1999 TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study Neurology 53 457 465
26. NL Sicotte RR Voskuhl 2001 Onset of multiple sclerosis associated with anti-TNF therapy Neurology 57 1885 1888 11723281 1:STN:280: DC%2BD3Mnnslenug%3D%3D (Pubitemid 33096700)
27. WH Robinson MC Genovese LW Moreland 2001 Demyelinating and neurologic events reported in association with tumor necrosis factor a antagonism: by what mechanisms could tumor necrosis factor a antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44 1977 1983 11592357 10.1002/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6 1:CAS:528:DC%2BD3MXpt12lsbg%3D (Pubitemid 33644038)
28. BM Segal CS Constantinescu A Raychaudhuri, et al. 2008 Repeated subcutaneous injections of IL12/23 p40 neutralizing antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomized, dose-ranging study Lancet Neurol 7 796 804 18703004 10.1016/S1474-4422(08)70173-X 1:CAS:528:DC%2BD1cXhtFWmsLrO
29. C Lucchinetti W Brück J Parisi, et al. 2000 Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination Ann Neurol 47 707 717 10852536 10.1002/1531-8249(200006)47:6<707::AID- ANA3>3.0.CO;2-Q 1:STN:280:DC%2BD3czgvFektA%3D%3D (Pubitemid 30390191)
30. AP Henderson MH Barnett JD Parratt JW Prineas 2009 Multiple sclerosis: distribution of inflammatory cells in newly forming lesions Ann Neurol 66 739 753 20035511 10.1002/ana.21800
31. MR Kotter WW Li C Zhao, et al. 2006 Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation J Neurosci 26 328 332 16399703 10.1523/JNEUROSCI.2615-05.2006 1:CAS:528:DC%2BD28XmtV2ltA%3D%3D (Pubitemid 43089546)
32. M Rodriguez AE Warrington LR Pease 2009 Human natural autoantibodies in the treatment of neurologic disease Neurology 72 1269 1276 19349608 10.1212/01.wnl.0000345662.05861.e4 1:CAS:528:DC%2BD1MXjslKrsL4%3D
33. Nielsen HH, Toft-Hansen H, Lambertsen KL, Owens T, Finsen B (2011) Stimulation of adult oligodendrogenesis by myelin-specific T cells. Am J Pathol, doi: 10.1016/j.ajpath.2011.06.006
34. M Bradl H Lassmann 2010 Oligodendrocytes: biology and pathology Acta Neuropathol 119 37 53 19847447 10.1007/s00401-009-0601-5
35. J Nakahara K Kanekura M Nawa, et al. 2009 Abnormal expression of TIP30 and arrested nucleocytoplasmic transport within oligodendrocyte precursor cells in multiple sclerosis J Clin Invest 119 169 181 19104151 1:CAS:528: DC%2BD1MXmtFCgsw%3D%3D
36. J Charcot 1868 Histologie de la sclérose en plaque Gazette des Hôpitaux 41 554 566
37. GA Schumacher G Beebe RF Kibler, et al. 1965 Problems of experimental trials of therapy in multiple sclerosis Ann N Y Acad Sci 122 552 568 10.1111/j.1749-6632.1965.tb20235.x
38. CM Poser DW Paty L Scheinberg, et al. 1983 New diagnostic criteria for multiple sclerosis: guidelines for research protocols Ann Neurol 13 227 231 6847134 10.1002/ana.410130302 1:STN:280:DyaL3s3gt1OgtQ%3D%3D (Pubitemid 13158528)
39. WI McDonald A Compston G Edan, et al. 2001 Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis Ann Neurol 50 121 127 11456302 10.1002/ana.1032 1:STN:280:DC%2BD38%2FitFOhug%3D%3D (Pubitemid 32591472)
40. CH Polman SC Reingold B Banwell, et al. 2011 Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria Ann Neurol 69 292 302 21387374 10.1002/ana.22366
41. S Vukusic C Confavreux 2003 Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis J Neurol Sci 206 135 137 12559500 10.1016/S0022-510X(02)00426-4 (Pubitemid 36143717)
42. C Confavreux S Vukusic 2006 Age at disability milestones in multiple sclerosis Brain 129 595 605 16415309 10.1093/brain/awh714 (Pubitemid 43278222)
43. BJ Hurwitz 2011 Analysis of current multiple sclerosis registries Neurology 76 S7 S13 21205683 10.1212/WNL.0b013e31820502f6
44. H Brønnum-Hansen N Koch-Henriksen E Stenager 2004 Trends in survival and cause of death in Danish patients with multiple sclerosis Brain 127 844 850 14960501 10.1093/brain/awh104 (Pubitemid 38478529)
45. M Filippi DW Paty L Kappos, et al. 1995 Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study Neurology 45 255 260 7854522 1:STN:280:DyaK2M7lslOnsA%3D%3D
46. NA Losseff SL Webb JI O'Riordan, et al. 1996 Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression Brain 119 2009 2019 9010005 10.1093/brain/119.6.2009 (Pubitemid 27032631)
47. LK Fisniku DT Chard JS Jackson, et al. 2008 Gray matter atrophy is related to long-term disability in multiple sclerosis Ann Neurol 64 247 254 18570297 10.1002/ana.21423
48. E Fisher JC Lee K Nakamura RA Rudick 2008 Gray matter atrophy in multiple sclerosis: a longitudinal study Ann Neurol 64 255 265 18661561 10.1002/ana.21436
49. U Bonati LK Fisniku DR Altmann, et al. 2011 Cervical cord and brain grey matter atrophy independently associate with long term MS disability J Neurol Neurosurg Psychiatry 82 471 472 20710012 10.1136/jnnp.2010.205021 1:STN:280:DC%2BC3M3mslCqtA%3D%3D
50. M Calabrese MA Rocca M Atzori, et al. 2010 A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis Ann Neurol 67 376 383 20373349
51. M Calabrese M Filippi P Gallo 2010 Cortical lesion in multiple sclerosis Nat Rev Neurol 6 438 444 20625376 10.1038/nrneurol.2010.93
52. A Kutzelnigg CF Lucchinetti C Stadelmann, et al. 2005 Cortical demyelination and diffuse white matter injury in multiple sclerosis Brain 128 2705 2712 16230320 10.1093/brain/awh641 (Pubitemid 41552953)
53. JW Peterson L Bø S Mörk, et al. 2001 Transected neuritis, apoptotic neurons and reduced inflammation in cortical multiple sclerosis lesions Ann Neurol 50 389 400 11558796 10.1002/ana.1123 1:STN:280: DC%2BD3MrhtFCnug%3D%3D (Pubitemid 32848742)
54. L Bø CA Vedeler H Nyland BD Trapp S Mörk 2003 Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration Mult Scler 4 323 331 10.1191/1352458503ms917oa (Pubitemid 36958014)
55. J van Horssen BP Brink HE De Vries P van der Valk L Bø 2007 The blood-brain barrier in cortical multiple sclerosis lesions J Neuropathol Exp Neurol 66 321 328 17413323 10.1097/nen.0b013e318040b2de (Pubitemid 46559025)
56. R Magliozzi O Howell A Vora, et al. 2007 Meningeal B-cell follicles in secondary-progressive multiple sclerosis associate with early onset of disease and severe cortical pathology Brain 130 1089 1104 17438020 10.1093/brain/awm038 (Pubitemid 47355604)
57. EJ Kooi JJ Geurts J van Horssen L Bø P van der Valk 2009 Meningeal inflammation is not associated with cortical demyelination in chronic multiple sclerosis J Neuropathol Exp Neurol 68 1021 1028 19680141 10.1097/NEN. 0b013e3181b4bf8f 1:CAS:528:DC%2BD1MXhtVygu77M
58. A Dal Biancco M Bradl J Frischer, et al. 2008 Multiple sclerosis and Alzheimer's disease Ann Neurol 63 174 183 10.1002/ana.21240 (Pubitemid 351355296)
59. R Magliozzi OW Howell C Reeves, et al. 2010 A gradient of neuronal loss and meningeal inflammation in multiple sclerosis Ann Neurol 68 477 493 20976767 10.1002/ana.22230 1:CAS:528:DC%2BC3cXhsVOrur7I
60. Howell OW, Reeves CA, Nicholas R et al (2011) Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. doi: 10.1093/brain/awr182, advance access
61. AJ Coles DA Compston KW Selmaj, et al. 2008 Alemtuzumab vs. interferon beta-1a in early multiple sclerosis N Engl J Med 359 1786 1801 18946064 10.1056/NEJMoa0802670
62. RT Naismith L Piccio JA Lyons, et al. 2010 Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial Neurology 74 1860 1867 20530322 10.1212/WNL.0b013e3181e24373 1:CAS:528:DC%2BC3cXntF2gtb4%3D
63. L Kappos EW Radue P O'Connor, et al. 2010 A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 362 387 401 20089952 10.1056/NEJMoa0909494 1:CAS:528:DC%2BC3cXhvVWltr4%3D
64. G Giovannoni G Comi S Cook, et al. 2010 A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis N Engl J Med 362 416 426 20089960 10.1056/NEJMoa0902533 1:CAS:528:DC%2BC3cXhvVaitr0%3D
65. PW O'Connor D Li MS Freedman, et al. 2006 A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses Neurology 66 894 900 16567708 10.1212/01.wnl.0000203121.04509.31 (Pubitemid 43739766)
66. PW O'Connor A Goodman AJ Willmer-Hulme, et al. 2004 Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects Neurology 62 2038 2043 15184611 (Pubitemid 38738218)
67. D Wynn M Kaufmann X Montalban, et al. 2010 Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomized, double-blind, placebo-controlled, add-on trial with interferon beta Lancet Neurol 9 381 390 20163990 10.1016/S1474-4422(10)70033-8 1:CAS:528:DC%2BC3cXltF2ktL4%3D
68. G Comi A Pulizzi M Rovaris, et al. 2008 Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study Lancet 371 2085 2092 18572078 10.1016/S0140-6736(08)60918-6 1:STN:280:DC%2BD1cvgsVegtQ%3D%3D (Pubitemid 351842581)